Self-amplifying may be the next frontier in RNA therapies
Self-amplifying RNA brings a differentiated immune profile, enables lower doses
With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s needed in a second generation of the technology.
Self-amplifying RNA is increasingly on companies’ radars as a path to vaccines for both infectious diseases and cancer given their ability to evoke strong cytotoxic T cell responses and enable lower, longer-lasting doses than “conventional” mRNA. ...